It is the fourth vaccine to receive the green light from the European Medicines Agency.
After those of Pfizer-BioNTech, Moderna and AstraZeneca, the serum from the American laboratory Johnson & Johnson obtained a place on the European market in mid-March.
It will be delivered in Europe from April 19, the company said on Monday.
It is currently only administered in the United States and South Africa, but it has also been approved in Canada.
In order to increase production and meet demand, Johnson & Johnson has made several agreements in recent months with laboratories and subcontractors in Europe, who will be responsible for its formulation or bottling: it s This involves Sanofi in France, Catalent in Italy, and IDT Biologika in Germany.
The active substance, which gives the vaccine its effectiveness, will come from the Johnson & Johnson site in Leiden in the Netherlands.
READ ALSO>
Johnson & Johnson's vaccine very effective against severe forms of Covid-19
This vaccine is the first, among those receiving a green light from the WHO, to require only one injection instead of two.
Another special feature: it is the only one that can be stored at refrigerator temperatures, which greatly facilitates its distribution.
The pharmaceutical group has also undertaken to sell it at cost price.
200 million doses ordered by the EU
The European Union, which has placed an order for 200 million doses from the American laboratory (with an option for 200 million additional doses), should receive some 55 million doses in the second quarter, Ursula von der Leyen explained in mid-March. , the President of the European Commission.
The laboratory, for its part, has not made public the exact schedule of its deliveries.
The vaccine is based on a viral vector, like those of AstraZeneca and Sputnik-V, according to a technology already used by the company, in particular against the Ebola virus.
It uses as a carrier another low virulent virus, transformed to add genetic instructions from part of the virus responsible for Covid-19.
Once in the cells, a typical SARS-CoV-2 protein is produced, educating the immune system to recognize it.